Perflutren
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00556 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 30 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | acute intermittent porphyria | KG + DL |
| 2 | nephrogenic syndrome of inappropriate antidiuresis | KG + DL |
| 3 | multidrug-resistant tuberculosis | KG + DL |
| 4 | myocardial ischemia | KG + DL |
| 5 | acute neonatal citrullinemia type I | KG + DL |
| 6 | adult-onset citrullinemia type I | KG + DL |
| 7 | coronary artery disease | KG + DL |
| 8 | anomalous left coronary artery from the pulmonary artery | KG + DL |
| 9 | tuberculoma | KG + DL |
| 10 | tuberculosis, avian | KG + DL |
| 11 | tuberculous ascites | KG + DL |
| 12 | inactive tuberculosis | KG + DL |
| 13 | tuberculosis, bovine | KG + DL |
| 14 | chronic tic disorder | KG + DL |
| 15 | urea cycle disorder | KG + DL |
| 16 | extrapyramidal and movement disease | KG + DL |
| 17 | benign shuddering attacks | KG + DL |
| 18 | porphyria | KG + DL |
| 19 | psychogenic movement disorders | KG + DL |
| 20 | benign paroxysmal tonic upgaze of childhood with ataxia | KG + DL |
| 21 | primary orthostatic tremor | KG + DL |
| 22 | tremor-nystagmus-duodenal ulcer syndrome | KG + DL |
| 23 | citrullinemia, type II, adult-onset | KG + DL |
| 24 | lingual-facial-buccal dyskinesia | KG + DL |
| 25 | allergic urticaria | KG + DL |
| 26 | female breast carcinoma | KG + DL |
| 27 | pyruvate dehydrogenase E1-alpha deficiency | KG + DL |
| 28 | lissencephaly | KG + DL |
| 29 | porphyria due to ALA dehydratase deficiency | KG + DL |
| 30 | subarachnoid hemorrhage (disease) | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.